TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET

Company Participants

Laine Morgan - Gilmartin Group, Investor Relations
Waleed Hassanein - President and Chief Executive Officer
Stephen Gordon - Chief Financial Officer

Conference Call Participants

Allen Gong - JPMorgan
William Plovanic - Canaccord
Joshua Jennings - TD Cowen
Ryan Daniels - William Blair
Matthew O'Brien - Piper Sandler
Suraj Kalia - Oppenheimer & Company
David Rescott - Baird
Mike Matson - Needham & Company

Operator

Good afternoon and welcome to the TransMedics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments.

Laine Morgan

Thanks, operator. Earlier today, TransMedics released financial results for the quarter ended September 30th, 2024. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call, including during the question-and-answer portion of the call that include forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements, including without limitation, our examination of operating trends, the potential commercial opportunity for our current and next generation products, services and technologies, the potential impact of investments in infrastructure, the potential timing, impact and outcomes of new clinical programs, as well as our future financial expectations, which include expectations for growth in our organization and guidance and/or expectations for revenue, gross margins and operating expenses in 2024 and beyond are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

Additional information regarding these risks and uncertainties appears under the heading Risk Factors of our Form 10-Q filed with the Securities and Exchange Commission on August 1st, 2024, our subsequent Form 10-Q filings and the forward-looking statements included in today's earnings press release, which are available at www.sec.gov and our website at www.transmedics.com.